Appointment of the Interim CEO to the Board

AI SummaryClose X

SkinBioTherapeutics plc has appointed Rachel Parsonage as a director to the Board, serving as Interim CEO, following the completion of regulatory due diligence by the Company's Nominated Adviser. Parsonage, aged 51, currently holds no shareholding in SkinBioTherapeutics and has a background in leading consumer beauty and wellness companies, including previous roles at KMI Brands and This Works. The company is awaiting the outcome of an external investigation and preparing for its HY results, with further announcements expected in due course.

Disclaimer*

UK 100

Latest directors dealings